In 1987, fewer than one in five American adults were obese, and by 1999, obesity was responsible for more than 300,000 excess ...

Pfizer trades at a 21.7% discount to peers on a 1-yr forward P/E basis, which is a point for the bullish arguments. Find out ...

Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

Pfizer yields 6.53% and trades at 9x earnings, while Altria offers 7.58% at 10.1x earnings. Pfizer's troubling 221% payout ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Pfizer stock has been weighed down lately, amid falling revenues and margins. The demand for the Covid-19 vaccine has taken a ...

Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is ...

Pfizer on Tuesday said it does not expect the Trump administration to make major changes to vaccine policy next year even as ...

Shares of Pfizer (NYSE: PFE) recently marched higher in response to a dividend payout raise and a forward-looking ...

We recently published a list of the 8 Best Dividend Leaders to Buy According to Wall Street Analysts. In this article, we are ...

Shares of Pfizer Inc. PFE inched 0.11% higher to $26.74 Tuesday, on what proved to be an all-around great trading session for ...

The company forecast revenue next year will grow slightly versus this year, when excluding certain factors. “The uncertainty ...